Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

Correction to: BMC Cancer 20, 1039 (2020)

https://doi.org/10.1186/s12885-020-07540-7

Following publication of the original article [1], the authors reported an error in the labeling of Table 5. The corrected Table 5 is given below.

Table 5.

Candidate genes involved in phenotypic response to afatinib treatment

a) Genes potentially involved in reduction of motility after afatinib treatment
SERPINE1 HBEGF	F3 ITGA2	CXCL8 HAS2	PLPP3 SPRY2	F2RL1	PTGS2	CYR61	CXCL1	SEMA6D	ETS1
b) Genes potentially involved in induction of apoptosis after afatinib treatment
BAX	BBC3	BCLAF1	CAV1	E2F1	FADD	FAF1	FAS	GSN	HYAL2
IL19	IL20RA	INHBB	LCK	LGALS9	NACC2	NF1	NFATC4	NKX3–1	PAK2
PARK7	PDCD5	PDIA3	PEA15	PPIF	PPP2R1B	PPP3CC	PRKRA	SFN	SFPQ
SKIL	SLC9A3R1	SMAD3	STK4	TGFBR1	TP73	TPD52L1	YWHAB	YWHAE	YWHAG
YWHAH	YWHAQ	YWHAZ	ZNF205

Genes that were regulated in MKN1 cells after 4 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of cell motility” were selected (a). Genes that were regulated in NCI-N87 but not in MKN1 and MKN7 cells after 24 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of apoptotic signaling pathway” were selected (b). Italics typeface indicates downregulation and bold typeface upregulation

The original article [1] has been corrected.